Healthcare Pharmaceuticals Limited (HPL) and Eli Lilly and Company today announced the launch of Trulicity® (dulaglutide) in Bangladesh. Trulicity® is the first once-weekly, injectable medication designed to improve blood sugar control in adults with Type 2 diabetes.
Trulicity® offers patient benefits beyond glycemic control and the convenience associated with a once-weekly dose. Studies done on Trulicity® have established its cardiovascular safety and weight reduction potential.
Trulicity® comes in an easy to use, single-dose pen that does not require mixing or measuring and can be administered at any time of the day, independent of meals. It is available in 0.75 mg and 1.5 mg doses. Special care has been taken in concealing the injector needle to address the fear of needles that some patients have.
Trulicity® is part of a class of drugs known as a glucagon – like peptide (GLP-1) receptor agonists. It is not insulin and mimics the effects of GLP-1, a natural hormone that helps keep blood sugar levels normal, by helping the body release its own insulin after food intake.
“Trulicity® will be marketed and distributed in Bangladesh by Healthcare Pharmaceuticals Ltd., a leading life science organization that believes in innovation, patient benefit and compliance. The launch of Trulicity® will open newer avenues in diabetes management and provide health care professionals with a better way to manage diabetes,” said Mr Halimuzzaman, DMD & CEO, Healthcare Pharmaceuticals Ltd.
“Diabetes is a big burden on the healthcare system in Bangladesh. More than 8 million people live with diabetes in the country and their treatment needs vary,” said Luca Visini, Managing Director for South Asia, Eli Lilly and Company. “Lilly has been a global leader in diabetes care since 1923. Trulicity® is an important addition to our diabetes portfolio in Bangladesh and this launch is an important milestone in our journey to help more and more patients and their caregivers with the treatment support they need,” he added.
“Type 2 diabetes is a progressive disease and in Bangladesh many patients do not meet their treatment goals. Trulicity® is a new, non-insulin, injectable that has been designed keeping patients’ needs and convenience in mind,” said Prof. A K Azad Khan, President, BADAS.
Trulicity® is a prescription drug that should be taken only on advice from registered physicians who deals the diabetic patients. When prescribed, it should be used as an adjunct to diet and exercise.
Eli Lilly and Company
Lilly is a global health care leader that unites caring with discovery to create medicines that make life better for people around the world. They were founded more than a century ago by a man committed to creating high-quality medicines that meet real needs, and today the company remain true to that mission in all their work. Across the globe, Lilly employees work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy and volunteerism.
To learn more about Lilly, please visit at lilly.com and lilly.com/newsroom.
Lilly Diabetes
Lilly has been a global leader in diabetes care since 1923, when they introduced the world’s first commercial insulin. Today they are building upon this heritage by working to meet the diverse needs of people with diabetes and those who care for them. Through research and collaboration, a broad and growing product portfolio and a continued determination to provide real solutions—from medicines to support programs and more—we strive to make life better for all those affected by diabetes around the world.
For more information, visit www.lillydiabetes.com.
Healthcare Pharmaceuticals Limited
Healthcare Pharmaceuticals Ltd. is one of the largest company in the pharmaceutical industry in Bangladesh manufacturing branded generic products for local and overseas market in Asia, Africa and CIS region and leading life science organization. Healthcare had started developing its factory in 1996 under the guidance and collaboration of F. Hoffmann La Roche, Switzerland. HPL is now manufacturing more than 300 products with all types of dosage forms and distributing throughout Bangladesh with a Sales Force of 2100 with a remarkable business growth in the industry. They always believe in innovation and patient benefit and compliance. Their prime focus always remains on quality. It leads them to tie up with reputed multinational pharma Eli Lilly for making available their novel medicine for the patients of Bangladesh.
For more information, please visit www.hplbd.com ♦
